Literature DB >> 12100184

The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival.

D B McKenna1, R J Lee, R J Prescott, V R Doherty.   

Abstract

BACKGROUND: The surgical management of primary cutaneous malignant melanoma usually involves an excision biopsy of the suspected lesion followed by wide local excision. No study has addressed whether a delay between these two surgical procedures influences patient outcome.
OBJECTIVES: To determine if the surgical interval (SI) between the diagnostic excision biopsy and wide local excision for primary cutaneous malignant melanoma affects recurrence or survival outcome.
METHODS: A cohort of 986 patients who had a diagnostic excision biopsy followed by wide local excision was identified from those registered on a specialist database that records the clinicopathological features, surgical treatment and follow-up information of all patients with malignant melanoma in Scotland. The cohort was divided into five arbitrary groups determined by the length of the SI as follows:< or =14 days, 15-28 days, 29-42 days, 43-91 days and > or = 92 days. Overall survival, disease-free survival and recurrence-free interval between the groups were compared univariately and multivariately.
RESULTS: The mean age at excision biopsy was 47.4 years and the median period of follow-up was 5 years (range 27 days to 20.7 years). The median SI was 30 days (range 1-468 days). The SI was: (i)< or =14 days for 130 (13%); (ii) 15-28 days for 320 (33%); (iii) 29-42 days for 262 (27%); (iv) 43-91 days for 251 (25%); and (v) > or = 92 days for 23 (2%) patients. The latter group was older, had thinner melanomas, a higher percentage of lesions on the head and neck, fewer superficial spreading malignant melanomas and ulceration present less often compared with patients treated earlier. Univariately, there was no significant difference in overall survival (P = 0.60) or disease-free survival (P = 0.24) between the groups. Although there was a statistically significant difference in the percentage of recurrence-free patients between the groups (P = 0.011), the better recurrence-free rates occurred in the 29-42 and 43-91 day groups. After adjusting for age, sex, tumour thickness, site, histology, ulceration and mitotic activity using Cox's proportional hazards model, there was no statistically significant difference in overall survival, disease-free survival and recurrence-free percentages between the surgical groups (P = 0.88, P = 0.44 and P = 0.084, respectively).
CONCLUSIONS: There was no evidence that survival outcome or recurrence was related to the time interval between the diagnostic excision biopsy and wide local excision of melanoma.

Entities:  

Mesh:

Year:  2002        PMID: 12100184     DOI: 10.1046/j.1365-2133.2002.04815.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  12 in total

1.  Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).

Authors:  Melody J Eide; Martin A Weinstock; Raymond G Dufresne; Suleka Neelagaru; Patricia Risica; Gary J Burkholder; David Upegui; Katharine A Phillips; Bruce K Armstrong; Leslie Robinson-Bostom
Journal:  J Invest Dermatol       Date:  2005-02       Impact factor: 8.551

2.  Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma.

Authors:  Daniel W Nelson; Stacey Stern; David E Elashoff; Robert Elashoff; John F Thompson; Nicola Mozzillo; Omgo E Nieweg; Harald J Hoekstra; Alistair J Cochran; Mark B Faries
Journal:  J Am Coll Surg       Date:  2017-06-28       Impact factor: 6.113

3.  Malignant melanoma: factors affecting the surgical interval from excision biopsy to definitive surgical management.

Authors:  M R Boland; R S Prichard; G A Bass; Z Al-Hilli; A Levendale; D Gibbons; K Sheahan; B Kirby; E W McDermott; D Evoy
Journal:  Ir J Med Sci       Date:  2014-06-11       Impact factor: 1.568

4.  Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.

Authors:  Ruzica Z Conic; Claudia I Cabrera; Alok A Khorana; Brian R Gastman
Journal:  J Am Acad Dermatol       Date:  2017-10-17       Impact factor: 11.527

5.  Association of Delays in Surgery for Melanoma With Insurance Type.

Authors:  Adewole S Adamson; Lei Zhou; Christopher D Baggett; Nancy E Thomas; Anne-Marie Meyer
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282

6.  Defining an acceptable period of time from melanoma biopsy to excision.

Authors:  Laura S Huff; Caroline A Chang; Jacob F Thomas; Margaret Cook-Shimanek; Paul Blomquist; Nellie Konnikov; Robert P Dellavalle
Journal:  Dermatol Reports       Date:  2012-01-17

Review 7.  Controversies in the diagnosis and treatment of early cutaneous melanoma.

Authors:  O A Orzan; A Șandru; C R Jecan
Journal:  J Med Life       Date:  2015 Apr-Jun

Review 8.  Management of primary skin cancer during a pandemic: Multidisciplinary recommendations.

Authors:  Brian C Baumann; Kelly M MacArthur; Jerry D Brewer; William M Mendenhall; Christopher A Barker; Jeremy R Etzkorn; Nathaniel J Jellinek; Jeffrey F Scott; Hiram A Gay; John C Baumann; Farrin A Manian; Phillip M Devlin; Jeff M Michalski; Nancy Y Lee; Wade L Thorstad; Lynn D Wilson; Carlos A Perez; Christopher J Miller
Journal:  Cancer       Date:  2020-06-01       Impact factor: 6.860

Review 9.  Melanoma of the Hand: Current Practice and New Frontiers.

Authors:  John Brad Turner; Brian Rinker
Journal:  Healthcare (Basel)       Date:  2014-03-06

10.  What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer.

Authors:  Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore
Journal:  Clin Oncol Res       Date:  2020-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.